Quantinno Capital Management LP Grows Stake in Takeda Pharmaceutical Co. $TAK

Quantinno Capital Management LP increased its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 20.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 1,289,326 shares of the company’s stock after acquiring an additional 219,999 shares during the period. Quantinno Capital Management LP’s holdings in Takeda Pharmaceutical were worth $23,878,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of TAK. Valeo Financial Advisors LLC grew its holdings in Takeda Pharmaceutical by 6.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock valued at $175,000 after purchasing an additional 632 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after buying an additional 713 shares during the last quarter. Abel Hall LLC raised its stake in shares of Takeda Pharmaceutical by 2.3% during the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock worth $632,000 after buying an additional 781 shares during the last quarter. Private Trust Co. NA boosted its position in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after buying an additional 783 shares in the last quarter. Finally, Checchi Capital Advisers LLC boosted its position in shares of Takeda Pharmaceutical by 5.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock worth $270,000 after buying an additional 786 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on TAK shares. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Finally, Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

More Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Q1 earnings and revenue beat estimates. Takeda reported quarterly EPS of $0.48 versus the $0.17 consensus estimate, while revenue reached $7.50 billion, ahead of expectations for $7.13 billion. The company cited resilient performance from its core portfolio and continued progress on launch preparations and research programs. Takeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Rise
• Positive Sentiment: Full-year guidance was raised or reaffirmed above consensus. Takeda provided fiscal 2026 EPS guidance of approximately $3.009 and revenue guidance of $29.6 billion, compared with analyst expectations of $1.57 EPS and $29.0 billion revenue. The outlook reinforces the view that operating performance remains solid. Takeda Announces FY2026 First Quarter Results
• Positive Sentiment: Analyst support remained favorable. Bank of America Securities analyst Koichi Mamegano reiterated a Buy rating after the quarterly beat and cited pipeline progress, while maintaining the existing price objective. Analyst Reiterates Buy on Takeda
• Positive Sentiment: Takeda will receive a $20 million development milestone payment from Keros Therapeutics. The payment reflects progress under the companies’ collaboration and provides non-operating cash inflow, although its effect is modest relative to Takeda’s overall revenue base. Keros Therapeutics to Receive Development Milestone Payment
• Neutral Sentiment: A UK court imposed an extended prosecution bar in patent litigation involving Millennium Pharmaceuticals, a Takeda subsidiary. The ruling is procedural and may restrict access to certain confidential information for attorneys involved in related patent matters; its direct financial impact on Takeda is not yet clear. Patents Court Imposes Extended Prosecution Bar
• Negative Sentiment: Takeda discontinued another Phase 2 celiac disease therapy. Ending the program narrows the company’s celiac pipeline to one remaining candidate and may reinforce concerns about R&D productivity, despite progress in other therapeutic areas. Takeda Scraps Another Phase 2 Celiac Disease Therapy

Takeda Pharmaceutical Stock Down 0.9%

Shares of NYSE:TAK opened at $17.09 on Friday. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The stock’s fifty day simple moving average is $16.26 and its 200-day simple moving average is $17.07. The company has a market capitalization of $54.77 billion, a P/E ratio of 50.28 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.87% and a net margin of 3.80%. As a group, equities research analysts forecast that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.